分子标志物指导下的转移性结直肠癌精准治疗概览

Overview of precision medicine in metastatic colorectal cancer under the guidance of molecular markers

本文综述了转移性结直肠癌相关靶向药物的作用机制、疗效及安全性方面的主要研究成果,在此基础上展望未来发展方向。抗血管生成类中贝伐单抗疗效显著;小分子药物疗效令人期待;抗EGFR信号通路类药物的适应证将更加精准,BRAF、HER2、PI3KCA等分子标志物的研究进一步推动了精确治疗的发展;免疫靶向治疗中PD-1/PD-L1在转移性结直肠癌的研究中也有所突破。未来在分子标志物指导下的转移性结直肠癌精确治疗更值得期待。

The main research achievements of functional mechanism,efficacy and safety of targeted drugs in metastatic colorectal cancer were reviewed in this paper for looking forward to the future development direction. Bevacizumab has remarkable curative effect in anti-angiogenesis drugs; curative effect of small molecule drug is worth expecting. Indications of drugs on the resistance to EGFR signaling pathway will be more accurate; the research of molecular markers such as BRAF,HER2 and PI3 KCA further promote the development of the precision medicine. The researches on PD-1 / PD-L1 in immune targeted drugs made a breakthrough in metastatic colorectal cancer. In the future under the guidance of molecular markers,precision medicine in metastatic colorectal cancer is more worth expecting than before.